Loading...
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
OBJECTIVES: Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. METHODS: Existing...
Na minha lista:
| Udgivet i: | Ann Rheum Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7788060/ https://ncbi.nlm.nih.gov/pubmed/33158881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-218398 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|